Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation ... where through a picture window an empty hammock swung wildly in the freezing January wind.

Mounjaro and Zepbound are by far Lilly's fastest-growing ... accelerate their performance and help contribute to the overall picture in a meaningful way. To me, oncology represents a hugely ...

Getty Images Pharmaceutical company Eli Lilly is ... The results come after the maker of weight-loss drugs Zepbound and Mounjaro in January lowered expectations for its fourth-quarter sales.